Alerus Financial NA lowered its stake in Shire PLC (NASDAQ:SHPG) by 1.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 23,346 shares of the biopharmaceutical company’s stock after selling 302 shares during the quarter. Alerus Financial NA’s holdings in Shire were worth $4,232,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in SHPG. Abrams Capital Management L.P. bought a new stake in shares of Shire in the 3rd quarter valued at $407,338,000. Third Point LLC bought a new stake in shares of Shire in the 3rd quarter valued at $290,032,000. PointState Capital LP increased its stake in shares of Shire by 4,642.0% in the 2nd quarter. PointState Capital LP now owns 711,296 shares of the biopharmaceutical company’s stock valued at $120,067,000 after acquiring an additional 696,296 shares in the last quarter. LMR Partners LLP bought a new stake in shares of Shire in the 2nd quarter valued at $55,664,000. Finally, Numen Capital LLP bought a new stake in shares of Shire in the 3rd quarter valued at $55,421,000. Institutional investors own 19.26% of the company’s stock.
SHPG has been the subject of several research analyst reports. Royal Bank of Canada set a $195.00 price objective on shares of Shire and gave the company a “buy” rating in a research note on Tuesday, October 23rd. Zacks Investment Research reiterated a “hold” rating on shares of Shire in a research note on Thursday, November 15th. BidaskClub lowered shares of Shire from a “hold” rating to a “sell” rating in a research note on Thursday, August 16th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a research note on Tuesday, July 31st. Finally, ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a research note on Friday, August 24th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Shire has a consensus rating of “Buy” and a consensus price target of $201.11.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 EPS for the quarter, missing the Zacks’ consensus estimate of $3.65 by ($0.01). The business had revenue of $3.87 billion for the quarter. Shire had a net margin of 30.63% and a return on equity of 12.70%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.81 EPS. Analysts forecast that Shire PLC will post 15.12 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Shire PLC (SHPG) Shares Sold by Alerus Financial NA” was reported by WKRB News and is owned by of WKRB News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/26/shire-plc-shpg-shares-sold-by-alerus-financial-na.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
See Also: Fundamental Analysis and Choosing Stocks
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.